- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00407472
ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency
This study was a Phase I, open label, randomized, 2-period, 2-sequence, crossover study designed to assess the relative bioavailability of Saizen administered by the ATS-1 needle-free injection device and a standard needle and syringe. Informed consent was obtained prior to screening. All screening assessments establishing subject eligibility were performed in the 21 days before dosing. Randomization Pre-dose on Day 1, subjects were randomized to one of the two treatment sequences: Sequence 1: SC Saizen administered by the Standard needle and syringe (Period 1) followed by the administration using the ATS-1 device (Period 2). Sequence 2: SC Saizen administered by the ATS-1 device (Period 1) followed by administration using the standard needle and syringe (Period 2).
Subjects were resident at the Unit from approximately 19:00 on Day -1 until Day 2 (approximately 30 hours (h) post dose) of each treatment period. An IV Stilamin infusion was commenced 1 h before. Saizen administration and stopped immediately after the last pharmacokinetic (PK) blood sample has been taken, i.e. a 25 h infusion. Stilamin was administered as a constant IV infusion at a rate of approximately 118 mg/h (40 mL/h), which corresponds to 1.65 mg/kg body weight/h for a person weighing 70kg. Dosing with Saizen occurred between approximately 0800 and 0900 h on Day 1 of each treatment period after an overnight fast of at least 10h. Subjects were dosed with Saizen at the same time on Day 1 in Periods 1 and 2. There was a minimum of 7-day washout between treatment periods 1 and 2.
Laboratory safety tests, ECGs were taken at protocol specified time points and blood samples for the assessment of glucose and growth hormone were taken immediately predose and 1, 2, 3, 4 4.5, 5, 5.5, 6, 7, 8, 12, 18 and 24 h post dose. A post-study visit took place 33+/- 3 days after dosing a treatment period 2.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription
Phase
- La phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male Subjects age 21 to 50
- Have given written informed consent
- Have a body weight greater than 60 kg and a body mass index (BMI) in the range of 22 30 (BMI - weight (kg) / height (m) 2)
- Have vital signs in the following normal range:
- Oral body temperature: 35.0 - 37.5 0C
- Blood Pressure (BP): Supine BP after at least 3 minutes of supine rest Systolic BP: 90 - 150 mm Hg, diastolic P: 50 - 95 mm Hg, Supine heart rate after at least 3 minutes of rest: 40 - 90 bpm
- Be non-smoker or smoke less than or equal to five cigarettes (or use an equivalent amount of tobacco per day and be willing not to smoke whilst resident in the clinical unit
- Be able to communicate well with the Principal Investigator and be willing to comply with the requirements of the entire study
- Agree to use barrier contraception (condom and spermicide) during the study and for three months following completion of the post study visit.
Exclusion Criteria:
- Existence of any surgical or medical condition which in the opinion of the Principal Investigator might interfere with the absorption, distribution, metabolism or elimination of the investigational medicinal product or with the aims of the study
- Have any clinically significant abnormality in the results of the screening safety laboratory tests
- Have an clinically significant abnormality on the 12-lead resting ECG at screening
- Have positive results from virology examination for Hepatitis surface antigen (HBsAg) (not due to vaccination), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV 1 and 2) at screening
- History or presence of hypertension or other significant cardiovascular abnormalities
- History or presence of cholelithiasis
- Significant history or clinical evidence of auto-immune, gastrointestinal, hematological, haemaoppoietic, hepatic, neurological, pancreatic or renal disease
- History or presence of diabetes
- Definite or suspected personal history or family history of adverse drug reaction or hypersensitivity to drugs with similar chemical structure to somatotropin or somtostatin
- Use of any chronic medication
- Presence or history of any serious allergy (requiring hospitalization or prolonged systemic treatment)
- History or presence of drug or alcohol abuse. The limits of alcohol consumption for inclusion in the study are defined as an average daily intake of 3 units or a maximum weekly intake of grater than 21 units (1 unit equals 340 mL of beer, 115 mL of wine or 43 mL or spirits)
- Loss or donation or more than 400 mL of blood in the 12 weeks before dosing
- Subjects who have used any prescription drugs within 2 weeks or over-the-counter medication (with the exception of paracetamol and multi-vitamins) within 1 week before dosing without prior approval from the investigator
- Administration of any investigational drug in the 12 weeks before dosing
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Anthony Priestley, MBChB MFPM, Bourn Hall Clinic
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 25821 (Autre identifiant: Stanford IRB)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur En bonne santé
-
AstraZenecaParexelComplété
Essais cliniques sur ATS-1 needle free device
-
Talita Cumi Ltd.Pas encore de recrutementDouleur musculo-squelettique | Peur de tomberRoyaume-Uni
-
Alcon ResearchComplétéErreurs de réfraction | AmétropieÉtats-Unis
-
Alcon ResearchComplété
-
Fred Hutchinson Cancer CenterActif, ne recrute pasMyasthénie grave | Neuromyélite optique | Maladie auto-immune | Polyneuropathie Démyélinisante Inflammatoire Chronique | Syndrome myasthénique de Lambert Eaton | Dégénérescence cérébelleuse | Syndrome de la personne raide | Syndrome Opsoclonie Myoclonie | Maladie neurologique auto-immune | Greffe autologue... et d'autres conditionsÉtats-Unis
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ComplétéTumeur des cellules hématopoïétiques et lymphoïdes | Lymphome | CD20 Positif | Néoplasme lymphocytaireÉtats-Unis
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ComplétéSyndrome myélodysplasique déjà traité | Syndrome myélodysplasique | Leucémie myéloïde aiguë récurrente | Leucémie aiguë lymphoblastique récurrente | Leucémie myéloïde aiguë en rémission | Leucémie aiguë lymphoblastique en rémission | Bénéficiaire d'une allogreffe de cellules souches hématopoïétiquesÉtats-Unis
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RésiliéLa leucémie lymphocytaire chronique | Leucémie prolymphocytaire | Syndrome de Richter | Bénéficiaire d'une allogreffe de cellules souches hématopoïétiquesÉtats-Unis
-
National Cancer Institute (NCI)ComplétéLeucémie myéloïde aiguë | Leucémie myéloïde aiguë récurrente de l'adulte | Syndrome myélodysplasique | Syndrome myélodysplasique avec excès de blastes | Syndrome myélodysplasique secondaire | Syndrome myélodysplasique de Novo | Leucémie monoblastique aiguë de l'adulte | Leucémie monocytaire aiguë... et d'autres conditionsÉtats-Unis
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ComplétéLymphome hodgkinien réfractaire | Lymphome non hodgkinien réfractaire à cellules B | Lymphome non hodgkinien réfractaire à cellules T | Receveur de greffe de cellules hématopoïétiquesÉtats-Unis
-
Fred Hutchinson Cancer CenterRetiréLymphome hodgkinien récurrent | Myélofibrose | Leucémie myéloïde aiguë résultant d'un syndrome myélodysplasique antérieur | Leucémie myélomonocytaire chronique | Syndrome myélodysplasique | Leucémie myéloïde aiguë récurrente | Leucémie myéloïde aiguë réfractaire | Néoplasme du système hématopoïétique... et d'autres conditionsÉtats-Unis